Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejo Rodriguez-Vida

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 studyThomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
European Urology|February 19, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerVincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
European Urology Oncology|October 14, 2023
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM StudyNuria Romero-Laorden, David Lorente, Guillermo de Velasco, et al.
European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
Clinical Genitourinary Cancer|August 19, 2025
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC StudyCristina Suárez, Òscar Reig Torras, Rafael Morales Barrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2019
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerElena Castro, Nuria Romero-Laorden, Angela Del Pozo, et al.
European Urology Open Science|April 13, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway InhibitorsPhilipp Mandel, Mike Wenzel, Felix Chun, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 studyThomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
European Urology|February 19, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerVincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
European Urology Oncology|October 14, 2023
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM StudyNuria Romero-Laorden, David Lorente, Guillermo de Velasco, et al.
European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
Clinical Genitourinary Cancer|August 19, 2025
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC StudyCristina Suárez, Òscar Reig Torras, Rafael Morales Barrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2019
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerElena Castro, Nuria Romero-Laorden, Angela Del Pozo, et al.
European Urology Open Science|April 13, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway InhibitorsPhilipp Mandel, Mike Wenzel, Felix Chun, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Pageof 9